Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherInvited Perspectives

Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage

Joseph A. Thie
Journal of Nuclear Medicine September 2004, 45 (9) 1431-1434;
Joseph A. Thie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

The ancients relied on just their visual interpretations of bright objects in the heavens. But advancing technology led to quantifications that properly normalized stellar distances to obtain absolute magnitudes. Somewhat analogously, in PET the standardized uptake value (SUV) came to be used as a tool to supplement visual interpretation. Uptake normalization as a fraction of the injected dose/unit weight has been in use as far back as 1941 (1). It was designated as the differential absorption ratio (DAR) and in the 1980s was being used in PET (2). Aliases such as the differential (or dose) uptake ratio (DUR) and standardized uptake ratio (SUR) occasionally appear in the literature.

The SUV is a special member of a class of dimensionless Q (= average activity per unit volume) ratios in use: tissue Q ÷ a normalizing Q. The latter can be contralateral, a background, an organ (e.g., liver, brain, and so forth), and, in particular, the whole body as SUV = tissue Q ÷ whole-body Q including tracer excretions = tissue Q ÷ injected dose per unit body volume, weight, or area. For the (time invariant) denominator—rather than a region of interest (ROI) around the whole body or using units of volume—there are traditional and convenient uses of weight or body surface area, allowing one to obtain a dimensioned (in mg/mL or m2/mL) result. The SUV (in mg/mL units), when averaged over the entire body, would equal the body density.

Commonly referred to as semiquantitative analysis, SUVs owe their popularity to a simplicity of method compared with others. In particular, it is of interest to compare the SUV with the more fully quantitative influx constant Ki = k1k3(k2 + k3), which requires more effort. Fortunately for diagnostic purposes, the end-of-scan SUV can be diagnostically essentially as discriminating as Ki. This is because when Ki exists (i.e., k3 ≠ 0), the 2 are quite proportional, with a population-average proportionality constant depending only on the time of SUV evaluation and the type of tracer (3,4)—and, in particular, being virtually independent of the tissue type.

A reliable reproducible measure of uptake is sought. An underlying reason for this stems from wanting to make comparisons. Intrapatient comparisons occur during therapy monitoring. Interpatient relative uptakes in the diagnostic process can be related to degrees of pathology. Moreover, as knowledge bases form for a particular disease, contributions arise from several institutions. To facilitate comparisons in all of these settings, one hopes to address any unwanted dispersion in a marker such as the SUV. These would be about its true physiologic value for a specific disease condition when there are differing methodology preferences— the main issue in this perspective.

In seeking reproducible uptake measures, the diagnostician has a large armamentarium from which to choose according to Hoekstra et al. (5). The authors discuss 9 classes of analytic methods suitable for PET image analysis. These, including the SUV class, have subclasses. For the SUV, these subclasses have historically arisen out of a motivation to seek refinements in determinations that can reduce variability from method variations.

METHOD-INFLUENCING FACTORS

The SUV is subject to errors that can arise in various quantitative methods (6,7). A criticism of being casual about SUV methodology has been made (8), citing several factors to consider. However, as part of addressing PET procedures in a broader sense, several consensus groups (9–13)—in discussing some of these factors—have made protocol suggestions. SUV-related topics, along with other factors, are organized in Table 1, which distinguishes confounding factors (i.e., potentially addressable by adjusting SUV results) and defined factors (i.e., biologic states conventionally considered as distinct entities). A possible application of Table 1 would be an aid while writing a Methods section when SUVs are being reported—that is, indicate fully, not just partially, how SUV is being measured.

View this table:
  • View inline
  • View popup
TABLE 1

Compilation by Category of Confounding Factors Influencing SUV Determination of Defined Tissue Type and State for Defined Population of Patients

An aspect of facilitating comparisons is using variability-reducing corrections for the factors in Table 1. Statistical error in an average or reference result can be reduced to the extent that significant changes in confounding variables (e.g., in tumor size, SUV’s time after injection, and so forth) are either used in corrections or kept minimal. It is desirous to have some reference conditions for the purpose of increasing the number of patients that can be grouped together in a study to gain statistical power. Also, diagnostic advantages accrue when variabilities from extraneous factors are reduced. That some SUV methods excel over others is seen in an example in which receiver-operating-characteristic (ROC) areas in 18F-FDG PET breast cancer diagnosis can vary from 0.81 to 0.91 among the methods (20).

In this issue of The Journal of Nuclear Medicine, on pages 1519–1527, Boellaard et al. (21) use simulation to systematically investigate several of the influences in Table 1. Rather than attempting to isolate each influencing effect while all others remain constant, their approach was a practical one: varying several readily controlled and clinically meaningful parameters (sometimes with individual effects therefore combining) in their simulation model. Their extensive data show how these affect R = the observed-to-actually-present counts ratio for an ROI = the observed ÷ the actual numerator of an SUV calculation. The scope of this research is not intended to address the last 3 factors in Table 1—that is, biologic factors and those influencing the denominator of an SUV calculation. The parameters varied are the type of ROI, the presence or absence of a spatial filter for one particular reconstruction algorithm, the noise equivalent counts collected, the number of pixels in the reconstruction matrix, uniform spheric lesion size, and the lesion-to-background ratio. The results show R ranging quite remarkably from as low as 0.4 to as high as 2.9 due to the synergism of having several parameters at once at their extremes. A much smaller, but more meaningful, measure of variability would be something like the SD of R expected due to random occurrences of various parameters having values typically encountered clinically.

Their simulation approach was to extract a part of the reconstruction code for their scanner and add features required for the investigation. Its results validate quite well against scan data from varieties of chest phantom conditions. Hence, the simulation could be used with confidence as influencing parameters are varied. It would appear that a subsequent use for this particular algorithm could possibly be using calculated R values to correct future SUVs for their off-normal parameters compared with some reference set of parameters. Strict validity of such corrections, however, would apply only to the chest region of this particular scanner and reconstruction for which the study was intended. With this approach, notwithstanding parameter differences, possible interinstitutional comparisons of corrected SUVs might be envisioned in which the PET hardware and software are a commonality. Otherwise, as Boellaard et al. (21) caution, SUV comparisons among institutions cannot be made casually—in contrast to acceptable comparisons they show possible for same-patient intrainstitutional studies.

This work is significant in several respects. It quantifies, for their particular chest phantom, the SUV variability encountered due to a variety of factors in combination. In particular, it explores a little-publicized upward biasing effect of higher pixel noises in ROIs based on the maximum single pixel value. The variabilities associated with all parameters studied are useful to observe, both by those measuring SUVs and by others using these. The work also demonstrates how simulation can be useful in addressing these influences. Possibly, some day, interinstitutional SUV comparisons may be more confidently made with research of this type used in combination with some standardization of methods.

SUV USAGE

Visual interpretation, as the bulwark of radiology, is typically combined with other information in diagnoses. Of the latter, the SUV is closely allied to the image reading process. Among the reader’s mental processes are qualitative comparisons of activities: within the image or with prior experience. Hence, unless comparisons are limited to images acquired by a frozen set of methods within an institution, the reader must be aware of the effects listed in Table 1. Having corrected SUVs available, along with knowledge of other factors influencing them, can be an aid.

If, after competing with or supplementing other analytic methods, the SUV has been chosen, Table 1 implies various choices to be made involving measurement parameters. The specific use of an SUV determination can have a bearing on the methods used. For example, correcting the 18F-FDG SUV for serum glucose (i.e., traditionally SUV × [glucose concentration ÷ a standard 100 mg/dL], though data for applicability to each unique tissue type should support this) can be appropriate when monitoring the same patient during therapy. On the other hand, many reports in the literature show no statistically proven advantage in applying this in studies composed of varieties of tissues. As another example, determining whether an intrinsically appropriate partial-volume correction is in fact beneficial can depend on prior experience—that is, whether an expected diagnostic advantage has been shown to be statistically significant in similar circumstances.

A popular usage of SUVs is their capability in helping to distinguish between benign and malignant lesions. For example, a study might find an SUV of 2.5 as appropriate for separating certain benign and malignant lesions. Caution, however, must be exercised using such a cutoff outside of the institution and the application for which it was determined. This is because there are institutional differences in the degree of diagnostic conservatism (i.e., choice of operating point on the ROC), the patient population, the specific pathology studied, and the specific methodology involved in determining the SUV. Interinstitutional variability stemming from the latter 3 categories is evident from Table 2, extracted from a meta-analysis of 18F-FDG PET studies, each having ≥20 patients with SUVs (22). But, if population character and pathology factors existing within the disease categories in Table 2 could be eliminated, a much better picture might emerge. This is suggested somewhat from a subset of 20- to 40-y olds within a meta-analysis (23) of institutions studying the coefficients of variation (CVs) of normal whole brains’ metabolic rates: The average of the CVs of individual studies within 26 institutions = 0.15; the CV contribution due solely to interinstitutional differences = 0.14; and the total (i.e., combined patient and institutional variabilities) CV of metabolic rates among 26 institutions = 0.20. These metabolic rate CVs contrast with the much larger SUV interinstitutional variabilities apparent within categories of Table 2.

View this table:
  • View inline
  • View popup
TABLE 2

Variability of Average SUVs Among Institutions for Particular Categories of 18F-FDG PET Studies

Finally, it might be tempting to suggest that, to avoid uncertainties or inaccuracies in an SUV approach, one should turn to fully quantitative methods such as Ki determinations. These determinations offer the benefit of avoiding issues of evaluation time and body size normalization, though typically they exhibit slightly higher intrainstitutional interpatient variability (24) than that found in SUVs. But the other factors in Table 1 still remain to be addressed. With the proportionality constant between SUV and Ki being only physiologically (and not methodology) based (3,4), there is a suggestion that if Table 2 were for Ki determinations, the conclusion could be the same: substantial variability among institutions within each particular category of studies.

CONCLUSION

Messages to carry away from the work of Boellaard et al. (21), supplemented by Table 1 presented here, are the desirability of standardization of protocols and analyses and that both measurer and user of SUVs have an awareness of all influencing factors. Many, though not all, of the latter also apply to influx and rate constant determinations and, to some extent, qualitative visual interpretations. Fortunately, within an institution there can be its preferred de facto standardized approach to SUVs. However, there might be changes over time or lack of acceptance by all, and special caution must be obviously be exercised in interinstitutional SUV usage, which presently is difficult. Helpful for the time being would be a better-documented specification of methods in publications than may be customary, considering Table 1 for guidance. To make the most of this diagnostic tool, as well as benefit from fully quantitative analytic methods, challenges for the future might include:

  • Further efforts by organizations to reach consensus on standardized approaches in scanner data acquisition and analysis, building on past accomplishments (9–13).

  • Highly automated user-friendly software that corrects and reports, perhaps by a simulation algorithm, SUVs along with values of their influencing parameters.

  • Along with patient data, possible reporting of scanned standard phantoms—recommended by a PET Data Analysis Working Group (9) and also suggested by Boellard et al. (21)—and possibly including SUVs, as known activity ratios of local to whole phantom, for the actual geometries and activities being encountered.

  • More research of the type reported in this issue.

Footnotes

  • Received Mar. 3, 2004; revision accepted Jul. 16, 2004.

    For correspondence or reprints contact: Joseph A. Thie, PhD, University of Tennessee, 12334 Bluff Shore Dr., Knoxville, TN 37922.

    E-mail: jathie{at}utk.edu

REFERENCES

  1. ↵
    Kenney JM, Marinelli LD, Woodard HQ. Tracer studies with radioactive phosphorus in malignant neoplastic disease. Radiology. 1941;37:683–690.
    OpenUrlCrossRef
  2. ↵
    Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med. 1985;26:37–42.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Thie JA. Clarification of a fractional uptake concept. J Nucl Med. 1995;36:711–712.
    OpenUrlFREE Full Text
  4. ↵
    Sadato N, Tsuchida T, Nakaumra S, et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumors. Eur J Nucl Med. 1998;25:559–564.
    OpenUrlCrossRefPubMed
  5. ↵
    Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27:731–743.
    OpenUrlCrossRefPubMed
  6. ↵
    Carson RE. Precision and accuracy considerations of physiological quantitation in PET. J Cereb Blood Flow Metab. 1991;11:A45–A50.
    OpenUrlPubMed
  7. ↵
    Alavi A, Smith R, Duncan D. What are the sources of error in measuring and calculating cerebral metabolic rates with fluorine-18-fluorodeoxyglucose and PET? J Nucl Med. 1994;35:1466–1468.
    OpenUrlFREE Full Text
  8. ↵
    Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836–1839.
    OpenUrlFREE Full Text
  9. ↵
    Rapoport SI. Discussion of PET workshop reports, including recommendations of PET Data Analysis Working Group. J Cereb Blood Flow Metab. 1991;11:A140–A146.
    OpenUrlPubMed
  10. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med. 1998;39:1302–1305.
    OpenUrlFREE Full Text
  11. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;25:1773–1782.
    OpenUrl
  12. Bartenstein P, Asenbaum S, Catafau A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [18F]FDG. Eur J Nucl Med Mol Imaging. 2002;10:BP43–BP48.
    OpenUrl
  13. ↵
    Bourguet P. 2002 Standards, options and recommendations for the use of [18F]-FDG (PET-FDG) in cancerology [in French]. Bull Cancer. 2003;90(spec no.):S1–S109.
  14. ↵
    Hoffman EF, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr. 1979;3:299–308.
    OpenUrlPubMed
  15. ↵
    Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308–1312.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Thie JA, Hubner KF, Smith GT. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol. 2002;4:238–244.
    OpenUrlCrossRefPubMed
  17. ↵
    Beaulieu S, Kinahan P, Tseng J, et al. SUV varies with time after injection in 18F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044–1050.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Schomberg A, Bender H, Reichel C, et al. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med. 1996;23:571–574.
    OpenUrlPubMed
  19. ↵
    Huang SC. Anatomy of SUV. Nucl Med Biol. 2000;27:643–646.
    OpenUrlCrossRefPubMed
  20. ↵
    Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18 FDG PET: quantitative image analysis. J Nucl Med. 1997;38:1186–1191.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–1527.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Thie JA, Hubner KF, Smith GT. The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med. 2000;41:1664–1672.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Wang GJ, Volkow ND, Wolf AP, Brodie JD, Hitzemann RJ. Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med. 1994;35:1457–1466.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Thie JA, Hubner KF, Smith GT. Standardized uptake value and influx constant: relationships and variabilities with model interpretation and clinical implications. Clin Positron Imaging. 1999;2:99–104.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 45 (9)
Journal of Nuclear Medicine
Vol. 45, Issue 9
September 1, 2004
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage
Joseph A. Thie
Journal of Nuclear Medicine Sep 2004, 45 (9) 1431-1434;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage
Joseph A. Thie
Journal of Nuclear Medicine Sep 2004, 45 (9) 1431-1434;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • METHOD-INFLUENCING FACTORS
    • SUV USAGE
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • THIS MONTH IN JNM
  • PubMed
  • Google Scholar

Cited By...

  • Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naive Diffuse Gliomas with Different Molecular Subtypes
  • Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma
  • In Patients We Trust: Reliability of Self-Reported Weight and Height in Nuclear Medicine Patients
  • Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network
  • Comparison of the Variability of SUV Normalized by Skeletal Volume with the Variability of SUV Normalized by Body Weight in 18F-Fluoride PET/CT
  • FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab
  • Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus
  • Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity
  • Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control
  • The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo 123I-CLINDE SPECT Imaging: A Test-Retest Study
  • Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation
  • PET Findings of Intramedullary Tumors of the Spinal Cord Using [18F] FDG and [11C] Methionine
  • Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value
  • Clinical Validation of 18F-AZD4694, an Amyloid-{beta}-Specific PET Radioligand
  • Mean-field modeling of thalamocortical dynamics and a model-driven approach to EEG analysis
  • Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues
  • Impact of Obesity on Nuclear Medicine Imaging
  • Quantifying and Reducing the Effect of Calibration Error on Variability of PET/CT Standardized Uptake Value Measurements
  • Time Course of Tumor SUV in 18F-FDG PET of Breast Cancer: Presentation of a Simple Model Using a Single Reference Point for Time Corrections of Tumor SUVs
  • Parallel in Vivo and in Vitro Selection Using Phage Display Identifies Protease-dependent Tumor-targeting Peptides
  • Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans
  • Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
  • Standards for PET Image Acquisition and Quantitative Data Analysis
  • Measuring Response with FDG-PET: Methodological Aspects
  • Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
  • Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study
  • Clinical applications and advances of positron emission tomography with fluorine-18-fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms
  • 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer
  • Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
  • Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
  • PET Evaluation of Lung Cancer
  • In Vivo Evaluation and Dosimetry of 123I-2-Iodo-D-Phenylalanine, a New Potential Tumor-Specific Tracer for SPECT, in an R1M Rhabdomyosarcoma Athymic Mouse Model
  • Simplified Quantification of Pittsburgh Compound B Amyloid Imaging PET Studies: A Comparative Analysis
  • PET for response assessment in oncology: radiotherapy and chemotherapy
  • Glucose-Normalized Standardized Uptake Value from 18F-FDG PET in Classifying Lymphomas
  • Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
  • Google Scholar

More in this TOC Section

  • Could FAP-Targeted Molecular Imaging Replace 18F-FDG for Standard-of-Care Oncologic PET?
  • Tau PET Visual Reads: Research and Clinical Applications and Future Directions
  • Radiomics in PET/CT: More Than Meets the Eye?
Show more Invited Perspectives

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire